SLC5A2 and type 2 diabetes mellitus: The Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial focusing on dapagliflozin [66], the CANagliflozin cardioVascular Assessment Study (CANVAS) trial on canagliflozin [29], and the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial on empagliflozin [67] validated the cardiovascular benefits of SGLT2-Is mentioned above.